# Allorion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allorion-therapeutics

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.alloriontx.com
- Total disclosed funding: $90M
- Latest round: Series B (Mar 9, 2023)
- Investors on record: 10

## About

Based in Guangzhou, China, and established in 2020, Allorion Therapeutics Inc. is a drug development that focuses on developing the next generation of targeted drugs for cancer and autoimmune diseases. The company team is comprised of experts in cancer biology and drug development. It has dual sites operating in Natick, Massachusetts, and Guangzhou, China. As of 2023, the company has 53 employees. Gregory Berk, Chief Medical Officer of the company, has served as the clinical senior vice president and chief medical officer of many well-known biotechnology and biomedical companies in the United States.

The company-developed fields include selecting validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of action, building data, and screening platforms, constructing and optimizing chemical libraries with allosteric and covalent modulators. Its main products include TYK2ARTS-011 and CDK2ARTS-021, etc. The company's products are used in diseases such as cancer and tumors.

## Funding rounds

- Series B, Mar 9, 2023, $50M — Qiming Venture Partners, 3SBio Inc., TF Capital, INCE Capital, Octagon Capital Investments, Elikon Venture, LongRiver Investments
- Series A, Aug 1, 2021, $40M — Qiming Venture Partners, IDG Capital, MED-FINE Capital, TF Capital, Firstlight Capital, Octagon Capital Investments, Elikon Venture

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- TF Capital — Series A, Series B
- Firstlight Capital — Series A
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series A, Series B
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series A, Series B
- 3SBio Inc. — Series B
- INCE Capital (https://capitalatlas.ai/funds/ince-capital) — Series B
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Series B